Systematic review of anticoagulant treatment of catheter-related thrombosis

Kreuziger, Lisa Baumann; Onwuemene, Oluwatoyosi A.; Kolesar, Emma; Crowther, Mark; Lim, Wendy

doi:10.1016/j.thromres.2015.08.020

Cited by 30 publications

(15 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PE was reported in 2.8%, recurrent DVT in 7%, and major haemorrhage in 2.8% of patients receiving anticoagulation with a median follow up between one and five years. 326 In an analysis of the RIETE registry (Registro Informatizado de Enfermedad TromboEmbólica), 67% of isolated CRT and 49% of CRT with PE were treated with long term LMWH vs. 27% and 47% treated with VKA for a median of 3.5 months in isolated CRT and 4.5 months in CRT with PE. 327 There are only few retrospective reports of the use of rivaroxaban.…”

Section: Prevention Of Catheter Related Thrombosismentioning

confidence: 99%

Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis

Kakkos

Gohel²,

Bækgaard

et al. 2021

European Journal of Vascular and Endovascular Surgery

446

323

View full text Add to dashboard Cite

Section: Prevention Of Catheter Related Thrombosismentioning

confidence: 99%

Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis

Kakkos

Gohel²,

Bækgaard

et al. 2021

European Journal of Vascular and Endovascular Surgery

446

323

View full text Add to dashboard Cite

“…7 In the absence of high-quality data, there is controversy on whether these patients require treatment and whether it is preferable to remove the device. The incidence of pulmonary embolism (PE) after UE-DVT is about 2%-2.8% 8,9 and there is limited prospective evidence that anticoagulation reduces the incidence of fatal or non-fatal PE. In our survey, surgeons were more likely to remove intravenous catheters than physicians in medical specialties.…”

Section: Discussionmentioning

confidence: 99%

“…[3][4][5] Most available information is derived from retrospective chart reviews and treatment recommendations remain inconclusive. [6][7][8][9] In the absence of definitive highquality data, the 2012 guidelines for the management of UE-DVT from the American College of Chest Physicians (ACCP) were based on less than ideal evidence (grade 2B or 2C) and on extrapolations from studies on lower extremity DVT. 10 The low quality of data may be the reason that the most recent ACCP guidelines from 2016 do not provide any recommendations on anticoagulation treatment or catheter management for catheter-related UE-DVT.…”

Section: Introductionmentioning

confidence: 99%

Variability in the management of line-related upper extremity deep vein thrombosis

et al. 2019

View full text Add to dashboard Cite

Objectives Central-venous devices are risk-factors for upper extremity deep vein thrombosis. We surveyed physicians to identify practice-patterns and adherence to American College of Chest Physicians guidelines. Methods The 13-question survey obtained physician-demographics and treatment-choices. Respondents were grouped into surgical and medical specialists. Data were reported as ratios and percentages, and compared using Fisher’s exact test. Results We received 143 responses from physicians; 65% treated one-to-two new cases/month. Most physicians (69.2%) used anticoagulation; 36.4% retained the catheter and 32.9% removed it. Medical-specialists retained catheters more often than surgeons ( p = 0.027). For recurrences, 84% repeated anticoagulation; 50.3% retained the catheter. A majority anticoagulated upper-extremity deep-vein thrombosis in long-term catheters for three months only (55.1%). Direct oral anticoagulants were used frequently (43.6%). Only 10% believed that existing guidelines were appropriate and only 2.8% followed all guidelines. Conclusion There is great variability in treatment-decisions for upper-extremity deep-vein thrombosis. The existing guidelines are considered inadequate and not followed by most physicians.

show abstract

“…In a systematic review on treatment of CRT, Baumann Kreuziger et al reported rates of recurrent VTE of 7.0% and rates of major bleeding of 2.8 to 4.9% of anticoagulated patients, with large variations in treatment modality and duration. 54 In a prospective pilot study, which investigated the outcome of anticoagulation with VKA in 74 patients with cancer and CRT, no recurrent VTE and four major bleeding events were reported. 55 However, based on data on management of cancerassociated VTE in general, LMWH is usually recommended over VKA.…”

Section: Evidence On Therapeutic Managementmentioning

confidence: 99%

How I Manage Cancer-Associated Thrombosis

Moik

2020

Hamostaseologie

View full text Add to dashboard Cite

In this concise review, we discuss some common clinical challenges in the management of patients with cancer-associated venous thromboembolism (VTE), a frequent complication in patients with cancer that increases morbidity and mortality. While direct oral anticoagulants (DOACs) have been established in clinical practice for anticoagulation in patients with VTE without cancer, their efficacy and safety in patients with cancer have not been assessed in randomized controlled trials until recently. The choice of the appropriate anticoagulant agent in the era of DOACs to treat patients with cancer-associated VTE is based on balancing the risk of recurrence against the risk of bleeding, and potential drug–drug interactions. However, the management of patients is challenged by special scenarios such as incidentally diagnosed pulmonary embolism and catheter-related thrombosis, and sometimes complicated by concomitant thrombocytopenia. We provide guidance for management of cancer-associated VTE in different clinical scenarios in a case-based manner and briefly review recent clinical studies and guidelines to explain our approach to management of the cases.

show abstract

Systematic review of anticoagulant treatment of catheter-related thrombosis

Cited by 30 publications

References 31 publications

Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis

Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis

Variability in the management of line-related upper extremity deep vein thrombosis

How I Manage Cancer-Associated Thrombosis

Contact Info

Product

Resources

About